Eisai has acquired the rights for manufacturing active pharmaceutical ingredients (API) for Japan from F Hoffman-La Roche for the insomnia treatment / anaesthesia induction agent flunitrazepam. The transfer of marketing authorisation held by ... Pharmaceutical Technology, 1 day ago
EISAI : acquires manufacturing rights for API from Roche to treat insomnia - 4 Traders, 22 hours ago
Eisai Co., Ltd. has announced that the medication administration support device e-OKUSURI-SAN® will be launched today for sale to pharmacies, medical institutions and caregiving facilities in Japan. This device supports treatment administration ...Global Hospital & Healthcare Management, 2 days ago Eisai to Participate in Access Accelerated, Global Partnership to Address Rise of Non-Communicable Diseases Sys-Con Media, 2 days ago Eisai acquires rights to manufacture API for flunitrazepam in Japan from Chugai & Roche PharmaBiz, 3 days ago Arena Pharmaceuticals and Eisai Amend Marketing and Supply Agreement for BELVIQ Globally Pharmacy Choice, 3 days ago
Arena Pharmaceuticals, Inc. ARNA announced that it has amended the marketing and supply agreement with Eisai Co., Ltd. ESALY for Belviq. Eisai will gain global commercialization rights to Belviq including the territories retained by Arena under the ...Yahoo! Finance, 2 weeks ago
More from: Nasdaq, Zacks.com...and 1 other sources
Japanese-based Eisai has announced the licensing of Fycompa (perampanel) for adjunctive treatment of partial-onset seizures in Jordan, Saudi Arabia and the United Arab Emirates (UAE). Fycompa can be used to treat the seizures with or without ...Pharmaceutical Technology, 2 weeks ago Drug improves epilepsy for people with partial onset seizures European Pharmaceutical Manufacturer, 1 month ago
It was a memorable occasion for the students of the Zilla Parishad High School at Yarada. Representatives of Eisai Pharmaceuticals India Private Ltd., from seven countries, visited their school on Tuesday. Yarada, a fishing village, is cut off ...The Hindu, 1 month ago
Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck's KEYTRUDA® pembrolizumab and Eisai's HALAVEN® eribulin mesylate Injection...
Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck's KEYTRUDA pembrolizumab and Eisai's HALAVEN eribulin mesylate Injection in Metastatic Triple-Negative Breast Cancer Presented at 2016 SABCS By a News Reporter-Staff News ...Pharmacy Choice, 4 weeks ago Combination of Merck's Keytruda and Eisai's Halaven shows positive effect in treatment-resistant breast cancer Seeking Alpha, 1 month ago Merck, Eisai Announce Interim Data Investigating Keytruda, Halaven Combination Nasdaq, 1 month ago BRIEF-Interim results from phase 1b/2 study evaluating the combination of Merck's Keytruda and Eisai's Halaven injection presented at 2016 SABCS (MRK) Business Insider, 1 month ago
Merck & Co., Inc. MRK and partner Eisai Co., Ltd. ESALY announced new interim data from a phase Ib/II study on the Keytruda-Halaven combination for the treatment of metastatic triple-negative breast cancer (TNBC). A look at Merck year-to-date ...Zacks.com, 1 month ago
More from: , Nasdaq...and 1 other sources
JERUSALEM, ISRAEL - MARCH 10: (ISRAEL OUT) Teva Pharmaceuticals workers pack drugs in a clean room at the company's manufacturing plant March 10, 2008 in Jerusalem. Teva is regarded as the world's largest generic drug maker. (Photo : Uriel Sinai/) ...ITechPost, 22 hours ago Shionogi : Participation in the global, multi-stakeholder collaboration, called Access Accelerated 4 Traders, 2 days ago 22 Biopharma Companies Partner and Launch First-of-its-kind Global Initiative to Address Rise of Non-Communicable Diseases International Business Times, 2 days ago 22 Biopharma Companies Partner, Launch First-of-Its-kind Global Initiative to Address Rise of Non-Communicable Diseases Pharmacy Choice, 20 hours ago
Eisai Co., Ltd (NASDAQ:ESALY) According to Zacks, Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following ...Mideast Time, 2 weeks ago Eisai Co., Ltd (ESALY) Lifted to Hold at Zacks Investment Research SleekMoney, 2 weeks ago Eisai Co., Ltd (ESALY) Upgraded to Hold by Zacks Investment Research WKRB News, 2 weeks ago
EISAI : First-in-class Epilepsy Treatment Fycompa(R) (perampanel) Launches in Jordan, Kingdom of Saudi Arabia and the United Arab Emirates - Press Release issued by Eisai
Following is the text of press release issued by Eisai Quote Fycompa(R) (perampanel) is now licensed for adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures in Jordan, Kingdom of Saudi Arabia and ...4 Traders, 2 weeks ago First-in-class Epilepsy Treatment Fycompa® (perampanel) Launches in Jordan, Kingdom of Saudi Arabia and the United Arab Emirates Yahoo! Finance, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!